Search results
Results from the WOW.Com Content Network
Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. [8] It is primarily used in the treatment of schizophrenia , bipolar disorder , and irritability associated with autism spectrum disorder ; [ 8 ] other uses include as an add-on treatment in major depressive disorder and tic disorders . [ 8 ]
Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease. [11] [13] [14] The most common side effects include akathisia (a constant urge to move) and weight gain. [12]
Pharmacological options for the specific treatment of FEP have been discussed in recent reviews. [35] [36] The goals of treatment for FEP include reducing symptoms and potentially improving long-term treatment outcomes. Randomized clinical trials have provided evidence for the efficacy of antipsychotic drugs in achieving the former goal, with ...
The atypical antipsychotics (AAP), also known as second generation antipsychotics (SGAs) and serotonin–dopamine antagonists (SDAs), [1] [2] are a group of antipsychotic drugs (antipsychotic drugs in general are also known as tranquilizers and neuroleptics, although the latter is usually reserved for the typical antipsychotics) largely introduced after the 1970s and used to treat psychiatric ...
In an exclusive clip, the talk show legend looks back on how easily he got prescription medication to manage his painful multiple sclerosis symptoms
No-penalty CDs and savings accounts are low-risk investments that offer a safe way to grow your money while earning interest. Here's how to match your cash to the best savings strategy for you.
A discredited study that set off a flurry of interest in using an antimalarial drug to treat COVID-19 has now been formally withdrawn. A scientific journal on Tuesday retracted the March 2020 ...
The percentage of patients who gained weight during the trial was 2.1% for brilaroxazine 15 mg, 5.9% for 50 mg, and 2.9% for placebo. This is a significant improvement over the currently prescribed third-generation antipsychotics aripiprazole (Abilify), brexpiprazole (Rexulti), and cariprazine (Vraylar). In comparable short-term (4-6 week ...